Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
Zanubrutinib resulted in an incremental gain of 0.084 QALYs at a cost saving of $26,768 per patient compared with ibrutinib, yielding an ICER of -$318,719/QALY.
The study evaluated the cost-effectiveness of zanubrutinib versus ibrutinib for Waldenström macroglobulinemia in China.
Zanubrutinib is a more effective and cost‐saving (dominant) first‑line treatment for Waldenström macroglobulinemia in China.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia